DOP Session 2

DOP10-18

  • DOP Session 2, Room C1 M0, Hall C, Bella Center
  • 17:30-18:30 Digital Oral Presentation Session 2: Mechanisms of intestinal inflammation
    Room: C1-M0, Hall C, Bella Center
    Chairs: Loris Riccardo Lopetuso, Rome, Italy
    Britta Siegmund, Berlin, Germany
    17:30-17:36 DOP10: Serum N-glycomic biomarkers predict treatment escalation in Inflammatory Bowel Disease
    A. Shubhakar    1, B. Jansen1, A. Adams2, K. Reiding3, N. Ventham4, D. Bergemalm5, P. Urbanowicz1, R. Gardner1, IBD-BIOM Consortium, J. Halfvarson6, J. Satsangi2, D. Fernandes1, M. Wuhrer7, D. Spencer1
    1    Ludger Ltd, Abingdon, United Kingdom, 2University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom, 3Utrecht University, Division of Biomolecular Mass Spectrometry, Utrecht, Netherlands, 4University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom, 5Örebro University, Department of Gastroenterology, Örebro, Sweden, 6Örebro University, Örebro, Sweden, 7Leiden University Medical Center, Center for Proteomics and Metabolomics, Leiden, Netherlands
      17:36-17:42 DOP11: Lymphocyte activation gene (LAG)-3 on T cells is a potential therapeutic target in Ulcerative Colitis
    S. Slevin    1, M. Tan1, C. Lahiff1, L. M. Wang2, B. Greenaway1, K. Lynch1, A. Geremia1, S. Hughes3, K. Leavens3, K. Nevin3, D. J. B. Marks3, R. Tarzi3, N. Srinivasan3, S. Travis1, C. Arancibia1, S. Keshav1
    1    University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom, 2Changi General Hospital, SingHealth, Department of Laboratory Medicine, Singapore, Singapore, 3GlaxoSmithKline, Experimental Medicine Unit, Stevenage, United Kingdom
      17:42-17:48 DOP12: Mutations in the X-linked inhibitor of apoptosis protein promote susceptibility to microbiota-induced intestinal inflammation
    S. Gopalakrishnan1, 2, Y. Zeissig2, A. Strigli1, M. Basic3, J. Hartwig2, J. Wang4, M. Muders5, G. Barreton5, J. F. Baines4, A. Bleich3, J. Hampe1, 5, S. Zeissig1, 2, 5
    1    Center for Regenerative Therapies Dresden, TU Dresden, Dresden, Germany, 2University Hospital Schleswig-Holstein, Kiel, Germany, 3Hannover Medical School, Hannover, Germany, 4Max-Planck Institute for Evolutinary Biology, Kiel, Germany, 5University Hospital Carl-Gustav Carus, Dresden, Germany
      17:48-17:54 DOP13: Immune profiling of adipose tissue in murine models of Inflammatory Bowel Disease (IBD)
    M. Letizia1, Y. Rodriguez Sillke1, F. Schmidt1, C. Günther2, D. Kunkel3, R. Glauben1, B. Siegmund1, C. Weidinger1
    1    Charité – Universitätsmedizin Berlin, Gastroenterologie, Infektiologie und Rheumatologie, Berlin, Germany, 2Universitätsklinikum Erlangen, Gastroenterologie, Erlangen, Germany, 3Charité - Universitätsmedizin Berlin, Berlin-Brandenburg Center for Regenerative Therapies, Berlin, Germany
      17:54-18:00 DOP14: TiO2 nanoparticles abrogate the protective effect of the autoimmunity-associated PTPN22R619W variant during acute DSS Colitis
    M. Schwarzfischer, L. Hering, E. Katkeviciute, A. Niechcial, K. Atrott, K. Bäbler, P. Busenhart, G. Rogler, M. Scharl, M. Spalinger
    University of Zürich, Department of Gastroenterology and Hepatology, Zürich, Switzerland
       18:00-18:06 DOP15: Metabolomics coupled with pathway analysis characterise metabolic changes in treatment-naive Ulcerative Colitis patients
    J. Diab1, T. Hansen1, R. Goll2, E. Jensen1, T. Moritz3, J. Florholmen4, G. Forsdahl1
    1Natural Products and Medicinal Chemistry Research Group, Department of pharmacy, University of Tromsø The Arctic University of Norway, Tromsø, Norway, 2Research Group of Gastroenterology and Nutrition, Department of Clinical Medicine, University of Tromsø The Arctic University of Norway, Tromsø, Norway, 3Swedish Metabolomics Center, Swedish University of Agricultural Sciences, Umeå, Sweden, 4Research Group of Gastroenterology and Nutrition, Department of Clinical Medicine, Tromsø, Norway
       18:06-18:12 DOP16: Endoplasmic reticulum stress in subepithelial myofibroblasts increases the TGF-β1 activity that regulates fibrosis in Crohn’s Disease
    C. Li    , J. Kuemmerle
    Virginia Commonwealth University, Internal Medicine, Richmond, United States      
      18:12-18:18 DOP17: AZD4205, a potent, GI tract-enriched, JAK1-selective inhibitor for treatment of Inflammatory Bowel Disease (IBD)
    M. Wang1 , T. John2, L. Zhang1, L. Zhu1, Y. Xu1, K. Chen1, S. Han1, J. Li1, F. Wang1, C. Deceneux3, 4, A. Behren3, 4, Z. Yang1
    1Dizal (Jiangsu) Pharmaceutical Co., Ltd, Shanghai, China, 2Austin Health, Heidelberg, Australia, 3Olivia Newton-John Cancer Research Institute, Heidelberg, Australia, 4La Trobe University, School of Cancer Medicine, Heidelberg, Australia
      18:18-18:24 DOP18: OSM neutralisation in IBD mucosal explant cultures reduces pro-inflammatory cytokine production
    A. Vossenkamper1, K. Foster2, K. Nevin2, G. Tannahill2, S. Flint2, T. T. McDonald1
    1    Blizard Institute, Barts and the London School of Medicine and Dentistry, Immunobiology, London, United Kingdom, 2GlaxoSmithKline, Immunoinflammation Unit, Stevenage, United Kingdom

Digital Oral Presentations
(as of January 2019)

  • DOP Session 1-5
    Thursday, March 7, 2019
  • DOP Session 6-10
    Friday, March 8, 2019
  • DOP Session 1 Advances in IBD pathophysiology
    DOP01-09
    Room: C1 M1
    Chairs: Javier Gisbert, Madrid Spain
    Maximilian Waldner, Erlangen, Germany
    DOP Session 2 Mechanisms of intestinal inflammation
    DOP10-18
    Room: C1 M0
    Chairs: Loris Riccardo Lopetuso, Rome, Italy
    Britta Siegmund, Berlin, Germany
    DOP Session 3 Translational science in IBD
    DOP19-27
    Room: C1 M2
    Chairs: Peter Bossuyt, Bonheiden, Belgium
    Axel Dignass, Frankfurt, Germany
    DOP Session 4 Practicalities of IBD patient care
    DOP28-36
    Room: C1 M3
    Chairs: Uri Kopylov, Tel Aviv, Israel
    Fernando Magro, Porto, Portugal
    DOP Session 5 Old and new treatment
    DOP37-45
    Room: C1 M4-5
    Chairs: Paolo Gionchetti, Bologna, Italy
    Anne Strik, Amsterdam, The Netherlands
  • DOP Session 6 Novel treatments
    DOP46-54
    Room C1 M4-5
    Chairs: Marc Ferrante, Leuven, Belgium
    Gionata Fiorino, Rome, Italy
    DOP Session 7 Recent advances of biologic therapies
    DOP55-63
    Room: C1 M3
    Chairs: Filip Baert, Roeselare, Belgium
    Shomron Ben-Horin, Ramat Gan, Israel
    DOP Session 8 Intestinal healing
    DOP64-72
    Room: C1 M2
    Chairs: Raja Atreya, Erlangen, Germany
    Marietta Iacucci, Birmingham, United Kingdom
    DOP Session 9 Surgery and IBD
    DOP73-81
    Room: C1 M1
    Chairs: Paulo Kotze, Curitiba, Brazil
    TBC
    DOP Session 10 Clinical epidemiology
    DOP82-90
    Room: C1 M0
    Chairs: Stefanos Bonovas, Milan, Italy
    Johan Burisch, Copenhagen, Denmark